Liu et al. 31 (2011) |
US CDC PrEP |
February 2005 to July 2007/January 2005 to July 2007 |
Yes |
Yes |
Cockroft-Gault creatinine clearance; spot urine calcium/creatinine ratio |
Each quarterly visit |
None |
Grohskopf et al. 34 (2013) |
US CDC PrEP |
February 2005 to July 2007/January 2005 to July 2007 |
Yes |
Yes |
Cockcroft-Gault creatinine clearance; serum creatinine; phosphorus |
Weeks 1, 3, 6, 9, 12, 15, 18, 21, and 24 |
DAIDS toxicity tables (January 2004) |
Grant et al. 10 (2010) |
iPrEx |
July 2007 to December 2009 |
Yes |
Yes |
Serum creatinine; Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucose; leukocyte esterase testing; urine phosphorus, calcium, creatinine, uric acid, protein, and glucose |
Weeks 4, 8, 12, 16, and 24 and then every 12 weeks |
Grade 1 or higher creatinine toxicity; grade 3 or higher phosphorous toxicity; grade 2, 3, or 4 laboratory; DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (2004) |
Solomon et al. 30 (2014) |
iPrEx |
July 2007 to December 2009 |
Yes |
Yes |
Serum creatinine; Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucose; leukocyte esterase testing; urine phosphorus, calcium, creatinine, uric acid, protein, and glucose |
Weeks 4, 8, 12, 16, and 24 and then every 12 weeks |
Grade 1 or higher creatinine toxicity; grade 3 or higher phosphorous toxicity; grade 2, 3, or 4 laboratory; DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (2004) |
Deutsch et al. 27 (2015) |
iPrEx |
July 2007 to December 2009 |
Yes |
Yes |
Serum creatinine; Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucose; leukocyte esterase testing; urine phosphorus, calcium, creatinine, uric acid, protein, and glucose |
Weeks 4, 8, 12, 16, and 24 and then every 12 weeks |
Grade 1 or higher creatinine toxicity; grade 3 or higher phosphorous toxicity; grade 2, 3, or 4 laboratory; DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (2004) |
Liu et al. 39 (2016) |
US PrEP Demonstration Project |
October 1, 2012, to January 23,2014 |
Yes |
|
Cockcroft-Gault creatinine clearance and eGFR (CKD-EPI); urine protein dipstick test |
Weeks 4, 12, 24, 36, and 48 |
DAIDS adverse event grading table version 1.0, December 2004, and the DAIDS Male Genital Grading Table |
Tang et al. 40 (2018) |
US PrEP Demonstration Project |
October 1, 2012, to January 23,2014 |
Yes |
|
Cockcroft-Gault creatinine clearance and eGFR (CKD-EPI) Urine protein dipstick test |
Weeks 4, 12, 24, 36, and 48 |
DAIDS adverse event grading table version 1.0, December 2004, and the DAIDS Male Genital Grading Table |
McCormack et al. 28 (2016) |
PROUD |
November 2012 to October 2016 |
Yes |
|
Serum creatinine; urine protein dipstick test |
Annualy and every 3 months |
None |
Hosek et al. 38 (2013) |
PrEPare ATN 08 3MV |
August 2005 to November 2006 |
Yes |
Yes |
Hepatic and pancreatic function tests; urine dipstick testing for protein and glucose |
Every 4 weeks for 24 weeks |
Expedited Adverse Event Reporting (grade 2 and higher) |
Hosek et al. 36 (2017) |
PrEPare |
January to September 2013 |
Yes |
Yes |
Renal function: phosphate, blood urea nitrogen, creatinine, and urine dipstick testing for protein and glucose; pancreatic function: amylase; hepatic function: AST, ALT, alcaline phosphatase, total bilirubin, and direct bilirubin |
Monthly in the first quarter (weeks 4, 8, and 12) and then quarterly until 48 weeks |
ATN adverse event severity grading table for adolescents (October 2006 to March 2011)/Manual for Expedited Reporting of Adverse Events to DAIDS (version 2.0, March 2011) |
Hosek et al. 37 (2017) |
PrEPare |
August 2013 to September 2014 |
Yes |
Yes |
Renal function: phosphate, blood urea nitrogen, creatinine, and urine dipstick testing for protein and glucose; pancreatic function: amylase; hepatic function: AST, ALT, alcaline phosphatase, total bilirubin, and direct bilirubin |
Monthly in the first quarter (weeks 4, 8, and 12) and then quarterly until 48 weeks |
ATN adverse event severity grading table for adolescents (October 2006 to March 2011)/Manual for Expedited Reporting of Adverse Events to DAIDS (version 2.0, March 2011) |
Havens et al. 35 (2017) |
ATN 117 |
December 2012 to October 2014 |
Yes |
Yes |
Serum creatinine, albumin, calcium, phosphate, glucose, protein, and retinol binding protein |
Weeks 4, 8, 12, 24, 36, and 48 |
None |
Grant et al. 29 (2018) |
067/ADAPT Study |
July 4, 2012, to May 6, 2014 |
Yes |
Yes |
Renal function: estimated creatinine clearance, phosphate; hepatic function: AST and ALT |
Weeks 4, 10, 18, and 30 |
None |
Wheeler et al. 33 (2019) |
HPTN 073 |
February 2013 to September 2014 |
Yes |
|
Cockcroft-Gault creatinine clearance; urine dipstick testing for protein and glucose |
At screening, 4 and 13 weeks after inclusion, and then quarterly; at screening and quarterly after inclusion |
None |
Mayer et al. 32 (2020) |
DISCOVER |
September 13, 2016, to June 30, 2017 |
Yers |
|
Cockcroft-Gault creatinine clearance; urinary RBP; lipids and fasting glucose; urine protein and urine protein to creatinine ratio |
Weeks 4 and 12 and then every 12 weeks |
None |
Ogbuagu et al. 41 (2021) |
DISCOVER |
September 13, 2016, to June 30, 2017 |
Yes |
|
Cockcroft-Gault creatinine clearance ; urinary RBP; lipids and fasting glucose; urine protein and urine protein to creatinine ratio |
Weeks 4 and 12 and then every 12 weeks |
None |